Cytokinetics Z Score
CYTK  Stock  USD 50.30 0.51 1.00% 
Cytokinetics  Z Score 
Cytokinetics Z Score Analysis
Cytokinetics' ZScore is a simple linear, multifactor model that measures the financial health and economic stability of a company. The score is used to predict the probability of a firm going into bankruptcy within next 24 months or two fiscal years from the day stated on the accounting statements used to calculate it. The model uses five fundamental business ratios that are weighted according to algorithm of Professor Edward Altman who developed it in the late 1960s at New York University..Current Cytokinetics Z Score  5.3 
Most of Cytokinetics' fundamental indicators, such as Z Score, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cytokinetics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
 
 
 
 

Cytokinetics Z Score Driver Correlations
Understanding the fundamental principles of building solid financial models for Cytokinetics is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Z Score. Since Cytokinetics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cytokinetics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cytokinetics' interrelated accounts and indicators.
Click cells to compare fundamentals
To calculate ZScore one would need to know current working capital of the company, its total assets, and liabilities, amount of latest retained earnings as well as earnings before interest and tax. ZScore can be used to compare the odds of bankruptcy of companies in a similar line of business or firms operating in the same industry. Companies with ZScores above 3.1 are generally considered to be stable and healthy with a low probability of bankruptcy. Scores that fall between 1.8 and 3.1 lie in a socalled 'grey area' with scores of less than 1, indicating the high probability of distress. Z Score is used widely by financial auditors, accountants, money managers, loan processers, wealth advisers, as well as day traders. In the last 25 years, many financial models that utilize z score has been proved to be successful as a predictor of corporate bankruptcy.
Compare to competition 
In accordance with the company's disclosures, Cytokinetics has a Z Score of 5.3. This is 178.52% lower than that of the Healthcare sector and 258.68% lower than that of the Biotechnology industry. The z score for all United States stocks is 160.78% higher than that of the company.
Cytokinetics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Cytokinetics from analyzing Cytokinetics' financial statements. These drivers represent accounts that assess Cytokinetics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cytokinetics' important valuation drivers and their relationship over time.
2017  2018  2019  2020  2021  2022 (projected)  
Net Income Per Employee  (932.77 K)  (817.61 K)  (780.08 K)  (689.9 K)  (586.69 K)  (633 K)  
Revenue Per Employee  97.58 K  242.31 K  172.23 K  302.58 K  191.9 K  212.66 K  
Average Assets  306.78 M  242.16 M  218.51 M  374.25 M  702.56 M  758.02 M  
Earnings Before Interest Taxes and Depreciation Amortization EBITDA  (122.85 M)  (101.25 M)  (113.78 M)  (109.5 M)  (196.6 M)  (201.77 M)  
Earnings Before Interest Taxes and Depreciation Amortization USD  (122.85 M)  (101.25 M)  (113.78 M)  (109.5 M)  (196.6 M)  (201.77 M)  
Earnings before Tax  (127.79 M)  (106.29 M)  (121.69 M)  (127.29 M)  (215.31 M)  (220.98 M)  
Average Equity  131.82 M  63.19 M  (8.08 M)  34.8 M  144.3 M  116.66 M  
Enterprise Value  353.14 M  360.05 M  639.82 M  1.41 B  3.99 B  4.3 B  
Free Cash Flow  (104.64 M)  (102.09 M)  (93.53 M)  (2.11 M)  (191.39 M)  (196.43 M)  
Invested Capital  168.94 M  189.91 M  363.43 M  558.56 M  926.72 M  999.89 M  
Invested Capital Average  203.78 M  194.17 M  230.69 M  388.78 M  814.76 M  879.08 M  
Market Capitalization  439.16 M  345.77 M  626.86 M  1.47 B  3.82 B  4.13 B  
Tangible Asset Value  294.81 M  211.18 M  289.81 M  533.8 M  841.32 M  907.74 M  
Working Capital  241.85 M  185.48 M  207.73 M  443.02 M  463.81 M  500.43 M 
Cytokinetics Fundamentals
Return On Equity  (279.90) %  
Return On Asset  (19.50) %  
Operating Margin  (343.79) %  
Current Valuation  3.34 B  
Shares Outstanding  84.39 M  
Shares Owned by Insiders  4.45 %  
Shares Owned by Institutions  103.98 %  
Number of Shares Shorted  11.81 M  
Price to Earning  (37.76) X  
Price to Book  16.93 X  
Price to Sales  65.28 X  
Revenue  65.03 M  
Gross Profit  (89.51 M)  
EBITDA  (220.48 M)  
Net Income  (257.66 M)  
Cash and Equivalents  608.97 M  
Cash per Share  7.11 X  
Total Debt  324.47 M  
Debt to Equity  2.79 %  
Current Ratio  9.33 X  
Book Value Per Share  2.97 X  
Cash Flow from Operations  (139.81 M)  
Short Ratio  5.94 X  
Earnings Per Share  (3.11) X  
Price to Earnings To Growth  (0.60) X  
Number of Employees  253  
Beta  1.18  
Market Capitalization  4.25 B  
Total Asset  115.24 M  
Retained Earnings  (887.78 M)  
Working Capital  81.46 M  
Current Asset  113.11 M  
Current Liabilities  31.65 M  
Z Score  5.3 
About Cytokinetics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cytokinetics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cytokinetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cytokinetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Cytokinetics, Incorporated, a latestage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company was incorporated in 1997 and is headquartered in South San Francisco, California. Cytokinetics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 253 people.
Cytokinetics Investors Sentiment
The influence of Cytokinetics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decisionmaking process regarding taking a position in Cytokinetics. The overall investor sentiment generally increases the direction of a stock movement in a oneyear investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Cytokinetics' public news can be used to forecast risks associated with investment in Cytokinetics. The trend in average sentiment can be used to explain how an investor holding Cytokinetics can time the market purely based on public headlines and social activities around Cytokinetics. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Cytokinetics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Cytokinetics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Cytokinetics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Cytokinetics.
Cytokinetics Implied Volatility  236.27 
Cytokinetics' implied volatility exposes the market's sentiment of Cytokinetics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Cytokinetics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Cytokinetics stock will not fluctuate a lot when Cytokinetics' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Cytokinetics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Cytokinetics' short interest history, or implied volatility extrapolated from Cytokinetics options trading.
Pair Trading with Cytokinetics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cytokinetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytokinetics will appreciate offsetting losses from the drop in the long position's value.Moving against Cytokinetics
0.66  KZIA  Kazia Therapeutics  Fiscal Year End 6th of October 2022  PairCorr 
The ability to find closely correlated positions to Cytokinetics could be a great tool in your taxloss harvesting strategies, allowing investors a quick way to find a similarenough asset to replace Cytokinetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cytokinetics  that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cytokinetics to buy it.
The correlation of Cytokinetics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between 1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cytokinetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cytokinetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cytokinetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better riskadjusted return on your portfolios.Continue to Cytokinetics Piotroski F Score and Cytokinetics Valuation analysis. Note that the Cytokinetics information on this page should be used as a complementary analysis to other Cytokinetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Backtesting module to avoid underdiversification and overoptimization by backtesting your portfolios.
Complementary Tools for Cytokinetics Stock analysis
When running Cytokinetics price analysis, check to measure Cytokinetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytokinetics is operating at the current time. Most of Cytokinetics' value examination focuses on studying past and present price action to predict the probability of Cytokinetics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cytokinetics' price. Additionally, you may evaluate how the addition of Cytokinetics to your portfolios can decrease your overall portfolio volatility.
Bond AnalysisEvaluate and analyze corporate bonds as a potential investment for your portfolios.  Go  
Balance Of PowerCheck stock momentum by analyzing Balance Of Power indicator and other technical ratios  Go  
Transaction HistoryView history of all your transactions and understand their impact on performance  Go  
Equity ValuationCheck real value of public entities based on technical and fundamental data  Go  
Portfolio VolatilityCheck portfolio volatility and analyze historical return density to properly model market risk  Go  
Portfolio HoldingsCheck your current holdings and cash postion to detemine if your portfolio needs rebalancing  Go  
Crypto CorrelationsUse cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins  Go  
Analyst RecommendationsAnalyst recommendations and target price estimates broken down by several categories  Go  
Performance AnalysisCheck effects of meanvariance optimization against your current asset allocation  Go 
Is Cytokinetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization 4.8 B  Quarterly Revenue Growth YOY 30.29  Return On Assets 0.17  Return On Equity 3.38 
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cytokinetics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.